| 7:30 AM - 8:30 AM |
Registration & Breakfast |
|
|
| 8:30 AM - 9:00 AM |
Welcome & Opening Remarks |
|
John Borer, President, Rodman & Renshaw LLC
|
|
Dr. Jeffery Z. Li, Partner, HT Pharma and Member,
BayHelix Group
and China Healthcare
Action Group
|
|
Miranda Tan, President, Excite Media Group
|
|
|
|
|
| 9:00 AM - 10:15 AM |
Key Notes: Expanding Horizons
in China -
Opportunities and Challenges |
|
Dr. Nancy T. Chang, CEO , Tanox, Inc
|
|
Dr. Yongtai Hou, Life Science R&D Head, CWGC
Group/
Shanghai Pharmaceutical
Group
|
|
Dr. Frank Kung, Managing General Partner, BioAsia
Investments.
|
|
|
| 10:15 AM - 10:30 AM
|
Networking Break |
|
|
| 10:30 AM
- 12:30 PM |
Session 1: Driving
Value Through Partnership |
|
Dr. James E. Foley, VP Corporate Business Development,
Bristol-Myers Squibb
Company
|
|
Dr. Nicholas Franco, Global Head, Business
Development and Licensing,
Primary Care, Novartis
Pharmaceuticals
|
|
Dr. James Li, Director Asia Pacific Franchise,
Merck & Co., Inc
|
|
Dr. Stella Xu, Global Alliance Director, Roche
|
|
Dr. Dan Zhang, Clinic Development Head, Sigma
Tau
|
|
Moderator: Dr. Steve Yang, Senior
Director, Strategic Management Group, Pfizer Inc |
|
|
| 12:30 PM - 1:30 PM |
Lunch Break |
|
|
| 1:30 PM - 2:45 PM |
Session 2: Creating Competitive
Edge Through Outsourcing |
|
Dr. Li Chen, Chief Scientific Officer, Roche
R&D Center China
|
|
Dr. Xiaodi Guo, VP Product Development , Abrika
Pharmaceuticals
|
|
Dr. Peiling Chen, Principal, Pharmaceutical
Sourcing Partners, Inc
|
|
Xiaolin Zhou, Senior Partner, JunHe Law Office
|
|
Moderator: Dr. Kewen Jin, Consultant,
Eli Lilly China |
|
|
| 2:45 PM - 3:00 PM |
Networking Break |
|
|
| 3:00 PM - 5:30 PM |
Session 3: Investment Perspective
and Chinese company Show case |
|
Introduction: Ray McQuiston, Partner,
Torys LLP |
|
Dr. Zhongyuan Li, Chairman and Jong Dae Lee,
CEO ,
China Healthcare
Holdings, Ltd
|
|
Dr. Robin Yuanhong Ma, President, Clingenix
Beijing
|
|
David Risinger, Senior Pharma Analyst, Merrill
Lynch & Co., Inc.
|
|
Dr. Victor Shi, Co-Founder and SVP of Corporate
Development, Bridge
Pharmaceuticals
|
|
Dr. David Sun, SVP, Capital Biochip Corporation.
|
|
Dr. Jianbo Sun, SVP, Beijing Tri-prime Genetic
Engineering Co., Ltd
|
|
Dr. Zhi Yang, General Partner, BioVeda Capital/Chairman,
Crimson Pharmaceutical
Ltd.
|
|
Dr. Nathan Zhang, President, Chipscreen Biosciences,
Ltd
|
|
Dr. Xi Zhao-Wilson, CEO, BioMarker Pharmaceuticals,
Inc.
|
|
Moderator: Dr. Bin Li, Equity
Research Analyst - Pharmaceuticals,
Merrill Lynch & Co., Inc. |
|
|
| 5:30 PM - 7:30 PM |
Networking and Cocktail Reception
|
